Johnson & Johnson tops 3Q expectations - 10/16/2018 6:01:34 AM

Desiree Burns
October 18, 2018

The company exchanged hands with 9326768 shares contrast to its average daily volume of 6.22M shares while its relative volume stands at 1.5. Wendell David Associates Inc.'s holdings in Johnson & Johnson were worth $14,233,000 at the end of the most recent reporting period. However, as 52 Week Range has little to no connection whatsoever with current news or forces affecting companies today, very few investors rely heavily on the metric. Financial Gravity Wealth Inc. acquired a new position in shares of Johnson & Johnson in the first quarter valued at approximately $105,000. Price Wealth Management Inc. increased its stake in shares of Johnson & Johnson by 39.5% during the 2nd quarter.

After all, if insiders are buying stock in their own company, they probably know something that a normal investor does not.

In related news, Controller, CAO Kapusta Ronald A sold 7,899 shares of the company's stock in a transaction that recorded on September 7th, 2018. The shares were sold at an average price of $137.18, for a total transaction of $1,083,584.82.

Investigating the productivity proportions of Johnson & Johnson stock, the speculator will discover its ROE, ROA, ROI remaining at 2.1%, 0.9%, and 15.7%, individually. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. This will give analytical advantage to a shorter-term trader since it pursues the price more intimately, and consequently produces less "lag" as comparison to the longer-term moving average. Following the transaction, the chief operating officer now directly owns 59,124 shares in the company, valued at $7,969,915.20. The disclosure for this sale can be found here.

Cricketers to take WAGs on foreign tours? No decision yet, says BCCI
It has been reported that after the first 10 days, WAGs will be able to be with their husbands till the conclusion of the tour. The CoA then asked Indian team manager Sunil Subramaniam to make a formal request to change the rule.

Shares of NYSE:JNJ opened at $136.56 on Wednesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.33 and a current ratio of 1.65. The stock price showed -9.69% downward in value from one year high price and revealed 12.92% higher in value from its one year low price. The firm has a market cap of $370.70 billion, a PE ratio of 18.35, a P/E/G ratio of 2.19 and a beta of 0.70. Earnings for the latest quarter rose to $3.93 billion, or $1.44 per share, after $3.76 billion, or $1.37 per share in the year-earlier period. The firm had revenue of $20.35 billion during the quarter, compared to analysts' expectations of $20.05 billion. Year-to-date, JNJ has declined -2.12%, versus a 4.85% rise in the benchmark S&P 500 index during the same period.

P/S, P/E, P/C and P/B/ SMA50, SMA 200: The price-to-sales is a valuation ratio that relates a company's stock price to its revenues.

Johnson & Johnson expects full-year earnings in the range of $8.13 to $8.18 per share, with revenue in the range of $81 billion to $81.4 billion. ValuEngine raised shares of Johnson & Johnson from a sell rating to a hold rating in a research note on Saturday, July 28th. It is meant to chart the current and historical strength or weakness of a stock or market based on the closing prices of a recent trading period. Credit Suisse Group set a $149.00 price objective on Johnson & Johnson and gave the stock a buy rating in a research note on Sunday. Finally, Goldman Sachs Group raised shares of Johnson & Johnson from a "sell" rating to a "neutral" rating in a research report on Thursday, July 12th. Analysts offer the company with a rating of 3 would be a sign of a Hold rating. Johnson & Johnson has an average rating of Hold and an average target price of $143.80.

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by over-the-counter products including Motrin and Tylenol analgesics, Zyrtec for upper respiratory issues and Imodium for digestive health products; beauty goods including Neutrogena among others, and domestic sales of Johnson's baby care products.

Other reports by

Discuss This Article